论文部分内容阅读
目的检测CD117及Nestin在卵巢上皮癌(EOC)中的表达水平,并探讨其临床意义。方法选择河北省邯郸市中心医院病理存档的石蜡标本80份,其中20份为正常卵巢标本,60份为卵巢上皮癌标本,采用免疫组化法(SP法)检测其CD117及Nestin的表达水平,并分析其与临床病理因素之间的关系。结果 CD117及Nestin在正常卵巢组织和卵巢上皮癌中的阳性表达率分别为10.0%、65.0%和5.0%、38.3%,差异有统计学意义(P<0.05)。CD117及Nestin在EOC组中的表达水平与其FIGO分期及病理分级有关,在Ⅲ-Ⅳ期、低分化组(G3)比Ⅰ-Ⅱ期、高中分化(G1、G2)组表达率高(P<0.05)。通过Kaplan-Meier生存曲线了解CD117和Nestin在预测卵巢癌预后中的价值。结论CD117与Nestin在卵巢上皮性癌中高表达,CD117及Nestin可能促进了卵巢上皮癌的发生、发展,并可能作为卵巢癌干细胞标志物用于判断卵巢上皮性癌的预后。
Objective To detect the expression of CD117 and Nestin in epithelial ovarian cancer (EOC) and to investigate its clinical significance. Methods Eighty paraffin specimens were collected from the Central Hospital of Handan City, Hebei Province, of which 20 were normal ovarian specimens and 60 were epithelial ovarian cancer specimens. The expressions of CD117 and Nestin were detected by immunohistochemistry (SP method) And analyze its relationship with clinicopathological factors. Results The positive rates of CD117 and Nestin in normal ovarian tissue and epithelial ovarian cancer were 10.0%, 65.0% and 5.0%, 38.3% respectively, with statistical significance (P <0.05). The expression of CD117 and Nestin in EOC group was correlated with their FIGO staging and pathological grade. The expression rates of CD117 and Nestin in stage Ⅲ-Ⅳ were higher than those in stage Ⅰ-Ⅱ and G1, G2 (P < 0.05). To investigate the value of CD117 and Nestin in predicting the prognosis of ovarian cancer by Kaplan-Meier survival curve. Conclusion CD117 and Nestin are highly expressed in epithelial ovarian cancer. CD117 and Nestin may promote the occurrence and development of ovarian epithelial carcinoma and may be used as markers of ovarian cancer stem cells to determine the prognosis of epithelial ovarian cancer.